These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 20103604)
1. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604 [TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901 [TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600 [TBL] [Abstract][Full Text] [Related]
4. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261 [TBL] [Abstract][Full Text] [Related]
5. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493 [TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631 [TBL] [Abstract][Full Text] [Related]
7. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology. Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304 [TBL] [Abstract][Full Text] [Related]
8. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants. Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627 [TBL] [Abstract][Full Text] [Related]
9. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Allen E; Walters IB; Hanahan D Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725 [TBL] [Abstract][Full Text] [Related]
10. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612 [TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans. Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073 [TBL] [Abstract][Full Text] [Related]